Use of proton pump inhibitors among Danish children: A 16-year register-based nationwide study.


Journal

Basic & clinical pharmacology & toxicology
ISSN: 1742-7843
Titre abrégé: Basic Clin Pharmacol Toxicol
Pays: England
ID NLM: 101208422

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 08 08 2018
accepted: 03 12 2018
pubmed: 18 12 2018
medline: 18 12 2019
entrez: 18 12 2018
Statut: ppublish

Résumé

Proton pump inhibitors (PPI) are among the most frequently used drugs in the developed countries. In recent years, their use among children and adolescents has been on the increase. Guidelines recommend use for a period no longer than 4-8 weeks. The aim of this study was to describe time trends in prescribing patterns of PPI use among children, with emphasis on persistence to therapy. We used the Danish nationwide healthcare registries and identified all Danish children (0-17 years old) who were provided with a filled in PPI prescription between 2000 and 2015. Based on descriptive analyses, we reported trends over time in annual use, prevalent and incident users. Moreover, we evaluated persistence to treatment and doses used over time. Analyses were stratified by age groups (0-4, 5-11 and 12-17 years). We identified 212 056 filled in PPI prescriptions prescribed to 78 489 children. The total annual use of PPIs among children increased eight times from 2000 to 2015. Omeprazole was most frequently used (60% of all use). The proportion of prevalent users increased from 0.1 in 2000 to 3.1 per 1000 children in 2015, while the rate of new users increased from 1.2 to 8.0 per 1000 child years. In general, persistence to PPIs was low: in the youngest age groups (14%), slightly more children were covered by treatment 12 months after the first prescription compared with the oldest age groups (5%). The use of PPIs among Danish children has increased substantially during the last 15 years. In general, treatment with PPIs among children was of short duration. Attention should be paid to indications and rationality behind initiation of therapy.

Identifiants

pubmed: 30556952
doi: 10.1111/bcpt.13191
doi:

Substances chimiques

Proton Pump Inhibitors 0
Omeprazole KG60484QX9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

704-710

Subventions

Organisme : Health Research
Organisme : Ministry of Health (Government of Catalonia)
ID : SLT002/16/00190

Informations de copyright

© 2018 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Auteurs

Ignacio Aznar-Lou (I)

Teaching, Research & Innovation Unit, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
Epidemiology and Public Health Networking Biomedical Research Centre (CIBERESP), Madrid, Spain.
Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.

Mette Reilev (M)

Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark.

Anders Bergh Lødrup (AB)

Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Diagnostic Centre, Silkeborg Hospital, Silkeborg, Denmark.

Maria Rubio-Valera (M)

Teaching, Research & Innovation Unit, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
Epidemiology and Public Health Networking Biomedical Research Centre (CIBERESP), Madrid, Spain.
School of Pharmacy, University of Barcelona, Barcelona, Spain.

Peter Fentz Haastrup (PF)

Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark.

Anton Pottegård (A)

Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH